How Pfizer Beat Q2 Estimates Despite Upjohn Sales Plunging 31%
Pfizer (NYSE: PFE) has had a very eventful year so far in 2020. The COVID-19 pandemic interfered with the timing of the company's planned merger of Upjohn with Mylan. It also prompted Pfizer to team up with German biotech BioNTech on the development of a COVID-19 vaccine candidate. Pfizer has also reported both good and bad news with its pipeline candidates over the last several months.
Now there's another event to add to Pfizer's eventful year: The company announced its second-quarter results before the market opened on Tuesday. Here are the highlights from Pfizer's Q2 update.
Image source: Getty Images.
Source Fool.com
